Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company dedicated to transforming patients' lives by developing a new class of drugs, Endosomal Escape Vehicles (EEV™), which can engage intracellular targets long considered undruggable and inaccessible. The company’s EEV therapeutics are designed to enable the efficient intracellular delivery of diverse therapeutic payloads to various organs and tissues, enhancing the therapeutic index. Through its proprietary, highly versatile, and modular EEV platform, Entrada is building a robust development portfolio based on oligonucleotides, antibodies, and enzymes for the potential treatment of neuromuscular, immunological, oncological, and central nervous system disorders. The company’s lead oligonucleotide programs include ENTR-601-44 for Duchenne Muscular Dystrophy (DMD) and a follow-up program targeting Myotonic Dystrophy Type 1 (DM1).